Please provide your email address to receive an email when new articles are posted on . Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs.
ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...
Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for ...
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma Authors retain all rights in ...
Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME) Favorable safety and ...
- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass., January 23, 2012-Millennium: The Takeda Oncology Company with ...
Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market, Industry Trends and Global Forecasts to 2035: Type of Biologic, Type of Therapy, Method of Administration, Fundamental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results